vs
自然阳光（NATR）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是自然阳光的1.5倍（$188.3M vs $123.8M），BRC Group Holdings, Inc.净利率更高（47.9% vs 3.3%，领先44.6%），自然阳光同比增速更快（4.7% vs -21.9%），过去两年自然阳光的营收复合增速更高（5.6% vs -15.4%）
自然阳光产品公司（简称NSP）主营膳食补充剂与个人护理产品的生产制造，产品涵盖草本补充剂、维生素、矿物质制剂等品类。公司总部设于犹他州利希，生产工厂位于犹他州西班牙福克，是该领域知名的健康产品生产商。
NATR vs RILY — 直观对比
营收规模更大
RILY
是对方的1.5倍
$123.8M
营收增速更快
NATR
高出26.6%
-21.9%
净利率更高
RILY
高出44.6%
3.3%
两年增速更快
NATR
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $123.8M | $188.3M |
| 净利润 | $4.1M | $90.3M |
| 毛利率 | 72.5% | 79.5% |
| 营业利润率 | 4.3% | 32.3% |
| 净利率 | 3.3% | 47.9% |
| 营收同比 | 4.7% | -21.9% |
| 净利润同比 | 1379.4% | 1710.8% |
| 每股收益（稀释后） | $0.23 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NATRRILY
| Q4 25 | $123.8M | $188.3M | ||
| Q3 25 | $128.3M | $215.3M | ||
| Q2 25 | $114.8M | $188.2M | ||
| Q1 25 | $113.2M | $197.2M | ||
| Q4 24 | $118.2M | $241.0M | ||
| Q3 24 | $114.6M | $225.5M | ||
| Q2 24 | $110.6M | $256.0M | ||
| Q1 24 | $111.0M | $263.4M |
净利润NATRRILY
| Q4 25 | $4.1M | $90.3M | ||
| Q3 25 | $5.3M | $91.1M | ||
| Q2 25 | $5.3M | $139.5M | ||
| Q1 25 | $4.7M | $-10.0M | ||
| Q4 24 | $-321.0K | $-5.6M | ||
| Q3 24 | $4.3M | $-284.4M | ||
| Q2 24 | $1.3M | $-433.6M | ||
| Q1 24 | $2.3M | $-49.2M |
毛利率NATRRILY
| Q4 25 | 72.5% | 79.5% | ||
| Q3 25 | 73.3% | 83.7% | ||
| Q2 25 | 71.7% | 81.3% | ||
| Q1 25 | 72.1% | 81.4% | ||
| Q4 24 | 72.0% | 79.8% | ||
| Q3 24 | 71.3% | 82.1% | ||
| Q2 24 | 71.4% | 84.5% | ||
| Q1 24 | 71.2% | 85.3% |
营业利润率NATRRILY
| Q4 25 | 4.3% | 32.3% | ||
| Q3 25 | 7.0% | 30.4% | ||
| Q2 25 | 3.7% | 5.7% | ||
| Q1 25 | 5.4% | -31.2% | ||
| Q4 24 | 3.8% | -69.2% | ||
| Q3 24 | 4.6% | -36.4% | ||
| Q2 24 | 5.1% | -90.8% | ||
| Q1 24 | 4.2% | -6.1% |
净利率NATRRILY
| Q4 25 | 3.3% | 47.9% | ||
| Q3 25 | 4.2% | 42.3% | ||
| Q2 25 | 4.6% | 74.1% | ||
| Q1 25 | 4.2% | -5.1% | ||
| Q4 24 | -0.3% | -2.3% | ||
| Q3 24 | 3.8% | -126.1% | ||
| Q2 24 | 1.2% | -169.4% | ||
| Q1 24 | 2.1% | -18.7% |
每股收益（稀释后）NATRRILY
| Q4 25 | $0.23 | $2.78 | ||
| Q3 25 | $0.30 | $2.91 | ||
| Q2 25 | $0.28 | $4.50 | ||
| Q1 25 | $0.25 | $-0.39 | ||
| Q4 24 | $-0.02 | $-0.01 | ||
| Q3 24 | $0.23 | $-9.39 | ||
| Q2 24 | $0.07 | $-14.35 | ||
| Q1 24 | $0.12 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $93.9M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $161.6M | $-171.5M |
| 总资产 | $261.1M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NATRRILY
| Q4 25 | $93.9M | $226.6M | ||
| Q3 25 | $95.6M | $184.2M | ||
| Q2 25 | $81.3M | $267.4M | ||
| Q1 25 | $86.5M | $138.3M | ||
| Q4 24 | $84.7M | $146.9M | ||
| Q3 24 | $78.7M | $159.2M | ||
| Q2 24 | $68.7M | $236.9M | ||
| Q1 24 | $77.8M | $190.7M |
总债务NATRRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
股东权益NATRRILY
| Q4 25 | $161.6M | $-171.5M | ||
| Q3 25 | $166.7M | $-260.5M | ||
| Q2 25 | $163.7M | $-351.7M | ||
| Q1 25 | $167.1M | $-496.8M | ||
| Q4 24 | $161.0M | $-488.2M | ||
| Q3 24 | $162.6M | $-497.6M | ||
| Q2 24 | $156.4M | $-218.3M | ||
| Q1 24 | $159.7M | $228.4M |
总资产NATRRILY
| Q4 25 | $261.1M | $1.7B | ||
| Q3 25 | $264.8M | $1.7B | ||
| Q2 25 | $254.9M | $1.5B | ||
| Q1 25 | $252.7M | $1.5B | ||
| Q4 24 | $240.9M | $1.8B | ||
| Q3 24 | $245.3M | $2.2B | ||
| Q2 24 | $235.8M | $3.2B | ||
| Q1 24 | $247.3M | $5.0B |
负债/权益比NATRRILY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $7.6M | — |
| 自由现金流率自由现金流/营收 | 6.1% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | 2.41× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $28.8M | — |
8季度趋势，按日历期对齐
经营现金流NATRRILY
| Q4 25 | $9.9M | $26.2M | ||
| Q3 25 | $18.5M | $-60.6M | ||
| Q2 25 | $4.3M | $-25.6M | ||
| Q1 25 | $2.6M | $184.0K | ||
| Q4 24 | $12.2M | $-2.7M | ||
| Q3 24 | $9.6M | $19.5M | ||
| Q2 24 | $1.3M | $111.5M | ||
| Q1 24 | $2.2M | $135.4M |
自由现金流NATRRILY
| Q4 25 | $7.6M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $-1.5M | — |
自由现金流率NATRRILY
| Q4 25 | 6.1% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -1.4% | — |
资本支出强度NATRRILY
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 3.3% | — |
现金转化率NATRRILY
| Q4 25 | 2.41× | 0.29× | ||
| Q3 25 | 3.46× | -0.66× | ||
| Q2 25 | 0.81× | -0.18× | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 0.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
